(1 - 20 from 20
)
Exelixis and Its Partner Ipsen Announce Positive Overall Survival...
ir.exelixis.com
... by Bernard Escudier , M.D., chair, Genitourinary Oncology Committee, Institut Gustave Roussy and Thomas Powles , M.D., clinical professor ...
GU Symposium 2016: Cabozantinib Improves Upon the Standard of Care...
ascopost.com
... lead study author Bernard Escudier, MD, Chair of the Genitourinary Oncology Committee at the Institut Gustave Roussy in Villejuif, France.
Patients with mRCC preferred pazopanib to sunitinib
www.healio.com
Bernard Escudier, MD, head of the immunotherapy unit at Institut Gustave Roussy in France, and colleagues enrolled 114 patients with mRCC ...
sorted by relevance / date